The drug is also used in the evaluation of breast nodules. Malignant breast tissues concentrate 99mTc MIBI to a much greater extent and more frequently than benign disease. As such, limited characterization of breast anomalies is possible. Scintimammography has a high
sensitivity and specificity for breast cancer, both more than 85%. More recently, breast radiologists administer lower doses of 99mTc sestamibi (approximately ) for Molecular Breast Imaging (MBI) scans which results in a high sensitivity (91%) and high specificity (93%) for breast cancer detection. It however carries a greater risk of
causing cancer, making it not appropriate for general
breast cancer screening in patients. The last reference listed refers to a dose, which is given with the Dilon single-head system, which requires a higher dose since only one camera is utilized (meaning the camera needs to be able to see through more tissue). A dose, which is used in the other two commercially available MBI systems is essentially equivalent to a mammogram () or a
tomosynthesis exam (). In order to keep the radiation doses to patients as low as reasonably achievable, MBI is usually limited to women with
dense breast tissue, where the medical benefit of the scan outweighs the potential risk of radiation exposure. For the same reason, the administered activity is kept low. This can potentially result in noisy images, which in turn causes inconclusive mammograms. Researchers continue to devote their time to improving the technology, changing scan parameters, and reducing dose to patients. == References ==